Equities Analysts Set Expectations for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Lifesci Capital upped their FY2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a report issued on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will earn ($2.50) per share for the year, up from their prior forecast of ($2.53). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Several other equities research analysts have also commented on the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Guggenheim reiterated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

Dianthus Therapeutics stock opened at $21.33 on Friday. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The stock’s 50 day simple moving average is $22.54 and its two-hundred day simple moving average is $24.83. The firm has a market cap of $631.30 million, a PE ratio of -8.53 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DNTH. R Squared Ltd acquired a new position in Dianthus Therapeutics in the 4th quarter valued at $26,000. Quest Partners LLC increased its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $59,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.